- Home
- ARCO vs WVE Comparison
ARCO vs WVE Comparison
Compare ARCO & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCO
- WVE
- Stock Information
- Founded
- ARCO 2007
- WVE 2012
- Country
- ARCO Uruguay
- WVE Singapore
- Employees
- ARCO N/A
- WVE N/A
- Industry
- ARCO Restaurants
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- ARCO Consumer Discretionary
- WVE Health Care
- Exchange
- ARCO Nasdaq
- WVE Nasdaq
- Market Cap
- ARCO 1.6B
- WVE 1.7B
- IPO Year
- ARCO 2011
- WVE 2015
- Fundamental
- Price
- ARCO $8.38
- WVE $11.13
- Analyst Decision
- ARCO Buy
- WVE Strong Buy
- Analyst Count
- ARCO 1
- WVE 10
- Target Price
- ARCO $12.00
- WVE $21.60
- AVG Volume (30 Days)
- ARCO 1.3M
- WVE 759.9K
- Earning Date
- ARCO 03-12-2025
- WVE 03-05-2025
- Dividend Yield
- ARCO 2.87%
- WVE N/A
- EPS Growth
- ARCO N/A
- WVE N/A
- EPS
- ARCO 0.69
- WVE N/A
- Revenue
- ARCO $4,501,397,000.00
- WVE $53,610,000.00
- Revenue This Year
- ARCO $6.00
- WVE N/A
- Revenue Next Year
- ARCO $3.11
- WVE $48.58
- P/E Ratio
- ARCO $12.13
- WVE N/A
- Revenue Growth
- ARCO 7.82
- WVE N/A
- 52 Week Low
- ARCO $7.02
- WVE $4.25
- 52 Week High
- ARCO $12.13
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- ARCO 63.47
- WVE 44.53
- Support Level
- ARCO $8.21
- WVE $10.79
- Resistance Level
- ARCO $8.48
- WVE $11.78
- Average True Range (ATR)
- ARCO 0.24
- WVE 0.69
- MACD
- ARCO 0.05
- WVE 0.05
- Stochastic Oscillator
- ARCO 88.80
- WVE 43.95
About ARCO Arcos Dorados Holdings Inc. Shares
Arcos Dorados Holdings Inc operates McDonald's-branded restaurants in approximately 20 countries and territories in Latin America and the Caribbean. It functions through two sources which include company-operated restaurants and franchised restaurants segment. Their menu includes hamburgers, McNuggets, salad, sandwiches, french fries and others.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.